References
-
1.
Pawlowska M, Pilarczyk M, Foksinska A, Smukalska E, Halota W. Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepat Mon. 2011;11(12):968-74. [PubMed ID: 22368680]. https://doi.org/10.5812/kowsar.1735143X.4223.
-
2.
Pawlowska M, Pilarczyk M, Halota W. Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children. Med Sci Monit. 2010;16(12):CR616-21. [PubMed ID: 21119580].
-
3.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65. https://doi.org/10.1016/S0140-6736(01)06102-5.
-
4.
Hu J, Doucette K, Hartling L, Tjosvold L, Robinson J. Treatment of hepatitis C in children: a systematic review. PLoS One. 2010;5(7):e11542. [PubMed ID: 20644626]. https://doi.org/10.1371/journal.pone.0011542.
-
5.
Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, et al. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology. 2011;53(4):1109-17. [PubMed ID: 21480317]. https://doi.org/10.1002/hep.24180.